CRISPR Therapeutics, MGH Partner to Develop T-Cell Cancer Therapies – Genetic Engineering & Biotechnology News
Press Telegraph |
CRISPR Therapeutics, MGH Partner to Develop T–Cell Cancer Therapies
Genetic Engineering & Biotechnology News CRISPR Therapeutics' interest in next-generation T–Cell cancer immunotherapies comes as both Kite Pharma and Novartis await FDA decisions on their CAR-T immuno-oncology treatments, with the companies emerging as leading developers of CAR-T … Building up its I/O ops, CRISPR Therapeutics allies with Marcela Maus at Mass General CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR … |
